Changes of serum LDH, CEA and β2-MG levels in non-Hodgkin's lymphoma patients in different situations and their clinical significance / 中国医师杂志

ABSTRACT

Objective@#To investigate the changes of serum carcinoembryonic antigen (CEA), lactate dehydrogenase (LDH), β2-microglobulin (β2-MG) levels in non-Hodgkin's lymphoma (NHL) patients and their clinical significance.@*Methods@#From February 2015 to February 2018, 54 patients with NHL who were hospitalized in Shiyan People's Hospital were selected as the observation group. All patients underwent two cycles of chemotherapy combined with radiation therapy. Another 54 healthy subjects were selected as the control group. To observe the changes of serum LDH, β2-MG, CEA levels in the control group, and compare the changes of serum LDH, β2-MG, CEA levels before and after treatment with different clinical stages, different conditions, and different effects in NHL.@*Results@#The levels of serum LDH, β2-MG, and CEA in the observation group were higher than those in the control group (P<0.05); the levels of serum LDH, β2-MG, and CEA in patients with NHL in stage Ⅲ to Ⅳ were higher than those in stage Ⅰ to Ⅱ (P<0.05); the levels of serum LDH, β2-MG, and CEA in patients with NHL in the middle-high-risk and high-risk groups were higher than those in the middle-risk and low-risk groups (P<0.05); after treatment, the levels of serum LDH, β2-MG, and CEA in stable disease (SD) and progression disease (PD) patients were not significantly different from those before treatment (P>0.05). While after treatment, the levels of serum LDH, β2-MG and CEA in complete relief (CR) and partial remission (PR) patients were lower than those before treatment (P<0.05), and were lower than those in SD and PD patients.@*Conclusions@#The level of serum LDH, β2-MG and CEA in patients with NHL increased, and the combined detection of the level changes is of great clinical value in the determination of clinical stage, malignant degree, clinical efficacy and prognosis of NHL patients.